Cargando…

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study

PURPOSE: This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC). MATERIALS AND METHODS: We retrospectively identified patients who received secondary treatment for PSR EOC at our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Se Ik, Lim, Hyunji, Kim, Hee Seung, Chung, Hyun Hoon, Kim, Jae-Weon, Park, Noh Hyun, Song, Yong-Sang, Lee, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873317/ https://www.ncbi.nlm.nih.gov/pubmed/35879854 http://dx.doi.org/10.4143/crt.2022.232

Ejemplares similares

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
por: Kim, Se Ik, et al.
Publicado: (2020)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
por: Kim, Se Ik, et al.
Publicado: (2020)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
por: Kim, Se Ik, et al.
Publicado: (2021)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study
por: Lim, Hyunji, et al.
Publicado: (2021)

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
por: Penson, Richard T., et al.
Publicado: (2020)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2023)

Machine Learning Models to Predict Survival Outcomes According to the Surgical Approach of Primary Radical Hysterectomy in Patients with Early Cervical Cancer
por: Kim, Se Ik, et al.
Publicado: (2021)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
por: Seol, Aeran, et al.
Publicado: (2022)

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
por: Raj, Hemanth, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
por: Lim, Hyunji, et al.
Publicado: (2022)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2023)

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer
por: Kim, Myeong-Seon, et al.
Publicado: (2022)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes
por: Sohn, Min-Hwan, et al.
Publicado: (2021)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
por: Ma, Jiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9p8eiieq4msaseugpacu77fj6u